NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Sentrx
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Sentrx Names O’Gorman President & General Manager - Sentrx, the leading provider of drug safety services to the life sciences industry, is pleased to announce the promotion of Michael O’Gorman from CFO to President & General Manager, effective immediately
Sentrx Names O’Gorman President & General Manager

 

NewswireToday - /newswire/ - Little Falls, NJ, United States, 2011/06/17 - Sentrx, the leading provider of drug safety services to the life sciences industry, is pleased to announce the promotion of Michael O’Gorman from CFO to President & General Manager, effective immediately.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Sentrx, the leading provider of drug safety services to the life sciences industry, and the largest hosting provider of the Oracle Argus Safety Suite, is pleased to announce the promotion of Michael O’Gorman from CFO to President & General Manager, effective immediately.

Commenting on the decision, CEO Charles T. Saldarini said,“Michael has the perfect blend of experience and skills to take on this role. He brings great command of our drug safety technology strategies as well as a strong grasp on the opportunities Sentrx is pursuing to gain continued efficiencies in our adverse event management business. As the leader of both our financial operations and our strategic alliances since 2008, Michael also brings deep financial acumen to the role.”

Michael O'Gorman has more than twenty years of experience in business and finance across diverse industries, including audit experience in the pharmaceutical/ life-science industry. He joined Sentrx in 2008 as Chief Financial Officer and in that capacity has managed all aspects of accounting, financial reporting, forecasting, human resources, and legal and office administration. Michael works as a member of the Sentrx executive team to achieve significant sales and revenue growth, establish pricing and sales strategies, and overall business planning.

“I am extremely grateful that the board of Sentrx has entrusted me in this role,” said Michael O’Gorman. “I look forward to expanding Sentrx’s footprint in the pharmaceutical/ life-science industry through continued development of innovative products and approaches to solving problems that companies face in dealing with the requirements of pharmacovigilance.”

Prior to joining Sentrx, Michael was Chief Financial Officer and Board Secretary for VirtualEdge Corporation, an innovator in the field of recruiting and talent lifecycle management solutions for HR organizations. He was one of three executives that took the company from a small revenue base in early 2003 to an acquisition by ADP in October 2006. For the next two year Michael served as Senior Director of Finance at ADP Employer Services, handling the integration of VirtualEdge with ADP's finance, legal, human resources and sales organizations. He was also the executive sponsor for a pre-employment product that serves the 1000-5000 employee population.

Previously, Michael was Vice President of Finance for Princeton eCom Corporation, a processor of electronic payments for more than 1,200 banks and billers. He handled the financial due diligence in connection with raising approximately $120M of private equity and spearheaded an initiative to redesign the company's payment engine and reconciliation processes to make the company more efficient. Michael also worked with the Office of the Comptroller of the Currency (OCC) in the U.S. Department of Treasury to ensure that the company's processes were in compliance with OCC regulations. Michael began his career with KPMG and held positions of increasing responsibility. While at KPMG he managed audits for several pharmaceutical/ life-science companies.

About Sentrx

Sentrx (sentrx.com) is an industry leader in providing outsourced drug safety solutions comprehensive pharmacovigilance solutions. Developing from a strong foundation in adverse event case processing and related drug data system management, the company has the most experienced and expertise personnel in the full-spectrum of drug safety solutions. Sentrx integrates business process outsourcing solutions, with a focus on providing flexible and scalable solutions, backed by the Sentrx Technology Services Group (TSG) with proven tools and technology platforms, Sentrx is safety.

Services from Sentrx are provided by all of our three core business solutions.

Sentrx TSG is our safety technology unit, which is a recognized leader among providers of Safety Systems. Sentrx TSG offers a proven expertise for accelerated system implementation, seamless upgrades, system conversions and client friendly maintenance. Our unit is highly knowledgeable in all facets of Data Management. We are one of the largest providers of regulated safety system hosting in the industry, with a world class hosting infrastructure supporting 24/7/365 global remote access.

Sentrx AEM is our full service pharmacovigilance and Adverse Event Management unit, offering both, end to end case processing and functional work-step support with fully integrated reporting and analysis of clinical and post marketing cases. We have developed a unique model, which reduces costs while ensuring the highest possible quality and we provide this through a range of dedicated client teams solutions, including on site placement and flexible resourcing.

Sentrx Medical Affairs is a complete Medical Affairs and Medical Information solution integrating call center support with medical information and scientific writing. Our capabilities include medical inquiries, product complaints, medical science liaison support and field sales support. Intake of adverse events is also typically provided.

Additionally, we provide services in Risk Management, including REMS and Signaling. Our expertise supports Strategic Safety Services covering planning, auditing and consultation and Special Projects.

Media Contacts:

Hemang Maisuria, P: 973-826-1815 / E: Hemang.maisuria[.]sentrx.com.
or
Michael O’Gorman, P: 973-826-1881 / E: Michael.Ogorman[.]sentrx.com.

Submitted by Logarithmic IMPACT (LogarithmicIMPACT.com) on behalf of Sentrx.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Sentrx

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Sentrx Names O’Gorman President & General Manager

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Sentrx - Hemang Maisuria 
973-826-1815 Hemang.maisuria[.]sentrx.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sentrx securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Sentrx / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Celltrion Pharm Selects TrackWise QMS for Scalability and Data Integrity
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MONOVERSE USA, Inc.

Visit  BizJobs.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)